Clinical Trials for Prostate Cancer
CA071-1000
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC). View details.
CAAA617A12402
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer. View details.
PSMACTION (CAAA817A12201)
A Phase II/III, Open-Label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Who Progressed On or After [177LU]LU-PSMA Targeted Therapy. View details.
